---

Department of Health

It is of course important to make such drugs available as quickly as possible, but certain systemic problems have been highlighted, such as ““NICE blight””. We need to take steps to prevent such exceptions from having to be made. Finally, given moves to increase the transparency of data relating to clinical trials, why do negotiations with the Treasury on the pharmaceutical price regulation scheme take place in such deep secrecy? Do the Department plan to make this process more open? I turn finally to other potential dangers and difficulties for patients—